CLINICAL TRIALS PROFILE FOR BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
✉ Email this page to a colleague
All Clinical Trials for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00367536 ↗ | Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 2006-08-01 | This study involves the experimental drug bazedoxifene acetate/conjugated estrogens (also called BZA/CE). This drug is not approved by the Food and Drug Administration (FDA). About 24 subjects will take part in this study. Each subject's participation in this study will last for about 10 weeks. During this study, each subject will receive 3 different types of BZA/CE tablets plus an oral solution containing only BZA. The purpose of this study is to learn how the tablet dosage forms dissolve and are absorbed by the body compared to the BZA oral solution. In addition, information will also be learned about the safety and tolerability of these dosage forms given to healthy postmenopausal women. |
| NCT00396799 ↗ | Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 2006-11-01 | The primary objective is to evaluate the bioequivalence between bazedoxifene/conjugated estrogens tablets produced using the current manufacturing process to bazedoxifene/conjugated estrogens tablets produced using a new manufacturing process |
| NCT00465075 ↗ | Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 2007-03-01 | The primary objective is to determine the effect of a high-fat meal on the bioavailability and PK of a single, oral dose of BZA/CE (PNP) 20mg/0.625 strength tablet, assessing both the BZA and CE components. |
| NCT00774267 ↗ | Study Evaluating Changes In Mammographic Breast Density | Completed | Pfizer | 2009-01-01 | The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene or placebo. The primary endpoint in this study is the change in mammographic breast density between baseline and month 24 for each group. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
Condition Name
Clinical Trial Locations for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
Trials by Country
Clinical Trial Progress for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
Clinical Trial Phase
Clinical Trial Sponsors for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
Sponsor Name
